BRPI0903901A2 - composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf - Google Patents

composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf

Info

Publication number
BRPI0903901A2
BRPI0903901A2 BRPI0903901A BRPI0903901A BRPI0903901A2 BR PI0903901 A2 BRPI0903901 A2 BR PI0903901A2 BR PI0903901 A BRPI0903901 A BR PI0903901A BR PI0903901 A BRPI0903901 A BR PI0903901A BR PI0903901 A2 BRPI0903901 A2 BR PI0903901A2
Authority
BR
Brazil
Prior art keywords
permeability
availability
methods
pathological angiogenesis
activation
Prior art date
Application number
BRPI0903901A
Other languages
English (en)
Portuguese (pt)
Inventor
Jones Christopher
Li Dean
London Nyall
Original Assignee
Univ Of Utah Res Foudation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Utah Res Foudation filed Critical Univ Of Utah Res Foudation
Publication of BRPI0903901A2 publication Critical patent/BRPI0903901A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
BRPI0903901A 2008-04-16 2009-04-16 composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf BRPI0903901A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4558008P 2008-04-16 2008-04-16
US7388008P 2008-06-19 2008-06-19
PCT/US2009/040848 WO2009129408A2 (en) 2008-04-16 2009-04-16 Compositions and methods for treating pathologic angiogenesis and vascular permeability

Publications (1)

Publication Number Publication Date
BRPI0903901A2 true BRPI0903901A2 (pt) 2017-05-23

Family

ID=41199735

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0903901A BRPI0903901A2 (pt) 2008-04-16 2009-04-16 composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf

Country Status (8)

Country Link
US (1) US20100222401A1 (enExample)
EP (1) EP2262524A4 (enExample)
JP (1) JP2011518178A (enExample)
KR (1) KR20100133881A (enExample)
CN (1) CN101687014A (enExample)
BR (1) BRPI0903901A2 (enExample)
CA (1) CA2693001A1 (enExample)
WO (1) WO2009129408A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672297A1 (en) 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions and methods for treating pathologic angiogenesis and vascular permeability
US8620879B2 (en) * 2009-10-13 2013-12-31 Google Inc. Cloud based file storage service
US20110087603A1 (en) * 2009-10-13 2011-04-14 Google Inc. Cloud based media player and offline media access
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
US8399404B2 (en) 2010-06-15 2013-03-19 The Hospital For Sick Children Methods and uses for inhibiting platelet coagulation
US10561707B2 (en) * 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
EP3148986A4 (en) * 2014-05-27 2018-01-10 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
RU2708375C2 (ru) * 2015-03-02 2019-12-06 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс Пептиды для ингибирования ангиогенеза
CN105726534A (zh) * 2016-02-17 2016-07-06 上海交通大学医学院附属仁济医院 SecinH3在制备抑制胃酸分泌药物中的应用
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
CN108929383B (zh) * 2017-05-26 2021-10-15 阿思科力(苏州)生物科技有限公司 重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用
US11077422B2 (en) * 2017-06-16 2021-08-03 Aquablok, Ltd. Spalling composite particles and methods of using them
CN108364289B (zh) * 2018-03-02 2021-05-14 成都斯斐德科技有限公司 Ivoct图像易损斑块自动检测方法
CN108715862A (zh) * 2018-05-28 2018-10-30 上海海洋大学 ddx19基因缺失斑马鱼突变体的制备方法
WO2021077064A1 (en) * 2019-10-18 2021-04-22 EMULATE, Inc. Brain-chip modeling neurodegeneration and neuroinflammation in parkinson's disease
US20240050444A1 (en) * 2020-03-14 2024-02-15 Levon Michael Khachigian Treatment methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480975A (en) * 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US6372958B1 (en) * 1999-05-26 2002-04-16 The University Of Utah Research Foundation Transgenic mouse with endogenous endoglin gene disruption
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
DK1572169T3 (da) * 2002-03-08 2013-10-21 Shanghai Inst Biol Sciences Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf
CA2490713A1 (en) * 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
DE102004055998A1 (de) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
DE102006054205A1 (de) * 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
CA2672297A1 (en) * 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions and methods for treating pathologic angiogenesis and vascular permeability
JP2012512170A (ja) * 2008-12-12 2012-05-31 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 血管バリア機能の促進および肺線維症の治療する組成物および方法

Also Published As

Publication number Publication date
KR20100133881A (ko) 2010-12-22
US20100222401A1 (en) 2010-09-02
WO2009129408A2 (en) 2009-10-22
JP2011518178A (ja) 2011-06-23
EP2262524A4 (en) 2012-07-11
WO2009129408A3 (en) 2009-12-23
EP2262524A2 (en) 2010-12-22
CN101687014A (zh) 2010-03-31
CA2693001A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
BRPI0903901A2 (pt) composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf
BRPI0807962A2 (pt) detecção de interrupção de sinal
EP2188917A4 (en) SIGNALING FOR THE PREAMBLE USED FOR DIRECT ACCESS
EP2906146A4 (en) CAPSULE EXPANDER DEVICES, SYSTEMS, AND METHODS FOR INHIBITING CAPSOLUTION AND STABILIZATION OF THE CAPSULE
EP2519207A4 (en) LEAD-FREE DETECTION SYSTEM FOR A VOIDABLE ARTICLE
DK2587805T3 (da) Tilstandsensartethedssignalering til intra-kodning
FR2934481B1 (fr) Etagere, en particulier pour des installations refrigerees.
BRPI0817288A2 (pt) Dispositivos vasculares trançados não tendo grampos de extremidade.
EP2491283A4 (en) BARRIER ASSEMBLY FOR A DRAINAGE CATHETER
BR112013016172A2 (pt) detecção de localização não autorizada e medidas preventivas.
DK3329888T3 (da) System til indføring af trommehindetrykudligningsrør
BRPI0919291A2 (pt) película parcialmente metalizada que tem propriedades de barreira.
EP2167733A4 (en) CONNECTION SYSTEM WITH IMPROVED LOCKING AREA
EP2326965A4 (en) SYSTEM FOR DETERMINING THE POSITION OF A REMOTE CONTROL UNIT
BR112012013829A2 (pt) "sistema de freio a disco em banho de óleo".
EP2330103A4 (en) NEW EPIGALLOCATECHINGALLATE TETRAMER AND VASCULAR ENDOTHELIAL FUNCTIONAL IMPROVEMENT THEREWITH
BRPI0906062A2 (pt) Inibidores de sinalização de brassinosteróides
EP3377776A4 (en) SYSTEMS WITH VALUABLE RELIABILITY FOR OPERATING HYDRAULICALLY OPERATED DEVICES AND RELATED METHODS
FR2929816B1 (fr) Etagere, en particulier pour des installations refrigerees
BRPI0911328A2 (pt) sistemas para prover um dispositivo de oclusão automático
BRPI0924646A2 (pt) películas de não pvc tendo camada de barreira
DK2387591T3 (da) Copolymer til inhibering af uorganiske aflejringer
EP2653158A4 (en) THERAPEUTIC AGAINST BLOOD BRAIN DISORDER
FR2959984B1 (fr) Structure de hublot ouvrant et affleurant pour bateau et bateau comportant au moins une telle structure
FR2932525B3 (fr) Protecteur pour terrasses,balcons et similaires.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]